Bone marrow cell chromosomal aberrations and styrene biotransformation in mice given styrene on a repeated oral schedule.
Styrene's capacity to induce chromosomal aberrations was studied in bone marrow cells of CD1 male mice. No mutagenic effect could be detected after either a 4-day treatment course with daily oral doses of 500 mg/kg or a 70-day course with daily oral doses of 200 mg/kg. Urinary elimination of styrene metabolites related to styrene-7,8-oxide formation (i.e. phenylethylene glycol, mandelic acid, benzoic acid, phenylglyoxylic acid and total mercapturic acids) was quantitatively evaluated in the group of mice given the 200 mg/kg dose. In parallel, kinetic studies were made on styrene and styrene-7,8-oxide blood concentrations in the same group of animals. These determinations were carried out on days 1 and 70 of treatment by spectrophotometric, gas chromatographic and mass fragmentographic procedures. Not even nanograms of styrene-7,8-oxide were found in the blood of styrene-treated mice. This suggests that the metabolite does not migrate from the cellular compartment where it is formed being immediately metabolized or irreversibly bound to cellular structures. This observation could well explain the lack of mutagenic effects observed.
D000284:Administration, Oral; D000818:Animals; D001711:Biotransformation; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology*; D002869:Chromosome Aberrations; D004852:Epoxy Compounds / Q000378:metabolism; D007700:Kinetics; D008297:Male; D051379:Mice; D020058:Styrene; D013343:Styrenes / Q000008:administration & dosage / Q000378:metabolism* / Q000633:toxicity
D004852:Epoxy Compounds; D013343:Styrenes; D020058:Styrene; C013690:styrene oxide